Related Experiment Videos
Therapeutic perspectives for type 2 diabetes mellitus: molecular and clinical insights
F Mauvais-Jarvis1, F Andreelli, H Hanaire-Broutin
1Service de Médecine B, Unité d'Endocrinologie et Maladies Métaboliques, Hôpital Lariboisière, Paris, France. FMauvaisJarvis@aol.com
Abstract:
Current antidiabetic agents do not suppress insulin resistance, do not reinstate physiological insulin secretion and fail to prevent the gradual loss of B-cell function. Thus, these molecules are unable to maintain long term euglycemia in all type 2 diabetic patients and there is a need for new antidiabetic drugs. Thiazolidinediones (TZD) are a new class of insulin sensitizers recently approved in Europe, in combination therapy with sulfonylureas or/and metformin, for the treatment of type 2 diabetes. TZD show beneficial effects on insulin action, glucose homeostasis and lipid metabolism despite a substantial weight gain. Their potential protective effect on B-cell function and on the development of macrovascular complication is of particular interest. Non TZD PPARgamma agonists are also under clinical trials. Other interesting therapeutic perspectives to treat insulin resistance lie in the development of inhibitors of protein tyrosine phosphatases and in the promotion of non insulin-dependent contraction-like muscle glucose uptake via stimulation of AMP protein kinase (AMPK). As to new insulin secretagogues, the phenylalanine derivative nateglinide is a first phase insulin secretion enhancer primarily intended at controlling post-prandial hyperglycemia. The most promising perspective to improve B-cell function lies in the development of glucagon-like peptide-1 (GLP-1) analogs. Clinical studies show beneficial effects on glucose homeostasis in type 2 diabetics and efficacy in sulfonylurea resistant patients without risk of hypoglycaemia. Animal studies predict beneficial effects on B-cell mass. Finally we will discuss the potential use of gene therapy to treat insulin resistance and B-cell dysfunction.
Insights
New antidiabetic drugs are needed as current treatments fail to address insulin resistance and B-cell decline. Promising agents include thiazolidinediones (TZD) and glucagon-like peptide-1 (GLP-1) analogs.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Current antidiabetic drugs inadequately manage type 2 diabetes, failing to reverse insulin resistance or preserve B-cell function.
- This necessitates novel therapeutic strategies for sustained glycemic control and prevention of disease progression.
Purpose of the Study:
- To review emerging antidiabetic agents targeting insulin resistance and impaired insulin secretion.
- To discuss novel therapeutic perspectives including thiazolidinediones (TZD), PPARgamma agonists, protein tyrosine phosphatase inhibitors, and AMP-activated protein kinase (AMPK) activators.
Main Methods:
- Review of current literature on novel antidiabetic drug classes.
- Analysis of clinical trial data for thiazolidinediones (TZD) and other emerging therapies.
- Exploration of potential therapeutic avenues such as gene therapy.
Main Results:
- Thiazolidinediones (TZD) improve insulin sensitivity and glucose homeostasis but cause weight gain.
- Glucagon-like peptide-1 (GLP-1) analogs show promise for improving glucose control and potentially increasing B-cell mass.
- Other agents like nateglinide and protein tyrosine phosphatase inhibitors offer alternative mechanisms for glycemic management.
Conclusions:
- Novel therapeutic approaches are crucial for managing type 2 diabetes, addressing limitations of existing treatments.
- Emerging drug classes like TZDs and GLP-1 analogs, alongside other strategies, offer improved glycemic control and potential B-cell protection.
- Future research directions include gene therapy for insulin resistance and B-cell dysfunction.